Company Filing History:
1 out of 123 
1 out of 263 Years Active: 2024
Title: Inventor Spotlight: Isabelle Anne Lemasson
Introduction: Isabelle Anne Lemasson is a distinguished inventor based in Cambridge, GB, recognized for her contributions to the field of medicinal chemistry. With a keen focus on innovative drug discovery, she has made significant strides in understanding and developing novel compounds that target critical pathways in cancer treatment.
Latest Patents: Lemasson holds a patent titled "Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them." This invention encompasses processes for preparing isoindolin-1-one derivatives, particularly the compound (2S,3S)-3-(4-chlorophenyl)-3-[(1R)-1-(4-chlorophenyl)-7-fluoro-5-[(1S)-1-hydroxy-1-(oxan-4-yl)propyl]-1-methoxy-3-oxo-2,3-dihydro-1H-isoindol-2-yl]-2-methylpropanoic acid. The patent also discusses the crystalline forms of this compound and its salts, providing valuable insights into its potential applications.
Career Highlights: Throughout her career, Lemasson has made substantial contributions while working with renowned organizations. She has been associated with Astex Therapeutics Limited and Cancer Research Technology Limited, where her expertise has been pivotal in advancing pharmaceutical research and development.
Collaborations: Isabelle has collaborated with notable figures in her field, including Steven Howard and Benjamin David Cons. These partnerships have resulted in fruitful exchanges of ideas and a collaborative approach to innovating cancer therapies.
Conclusion: Isabelle Anne Lemasson exemplifies the spirit of innovation in the pharmaceutical industry. Her groundbreaking patent highlights her dedication to finding effective solutions in cancer treatment. As research continues to evolve, Lemasson's work will undoubtedly leave a lasting impact on both the scientific community and patients worldwide.